Cite
HARVARD Citation
Catenacci, D. et al. (2020). Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. Lancet oncology. 21 (8), pp. 1066-1076. [Online].